Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
PURPOSE: To characterize exposure-response relationships of AMG 386 in a phase 2 study in advanced ovarian cancer for the facilitation of dose selection in future studies. METHODS: A population pharmacokinetic model of AMG 386 (N = 141) was developed and applied in an exposure-response analysis using data from patients (N = 160) with recurrent ovarian cancer who received paclitaxel plus AMG 386 (3 or 10 mg/kg once weekly) or placebo. Reduction in the risk of progression or death with increasing exposure (steady-state area under the concentration-versus-time curve [AUC(ss)]) was assessed using Cox regression analyses. Confounding factors were tested in multivariate analysis. Alternative AMG 386 doses were explored with Monte Carlo simulations using population pharmacokinetic and parametric survival models. RESULTS: There was a trend toward increased PFS with increased AUC(ss) (hazard ratio [HR] for each one-unit increment in AUC(ss), 0.97; P = 0.097), suggesting that the maximum effect on prolonging PFS was not achieved at the highest dose tested (10 mg/kg). Among patients with AUC(ss) ≥ 9.6 mg h/mL, PFS was 8.1 months versus 5.7 months for AUC(ss) < 9.6 mg h/mL and 4.6 months for placebo. No relationship between AUC(ss) and grade ≥ 3 adverse events was observed. Simulations predicted that AMG 386 15 mg/kg once weekly would result in an AUC(ss) ≥ 9.6 mg h/mL in > 90% of patients with median PFS of 8.2 months versus 5.0 months for placebo (HR [15 mg/kg vs. placebo], 0.56). CONCLUSIONS: Increased exposure to AMG 386 was associated with improved clinical outcomes in recurrent ovarian cancer, supporting the evaluation of a higher dose in future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels
Rustin, G. J. S., Marples, M., Nelstrop, A. E., Mahmoudi, M., & Meyer, T. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4054 · Cited by 201 · cited 1×
“0 [19], clinical progression (per investigator), CA-125 progression (Gynecologic Cancer Intergroup criteria [20]), or death.”
Cited by
Rini, B., Szczylik, C., Tannir, N. M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L. Y., Fishman, M., Ramlau, R., Ravaud, A., et al. (2012) · Cancer · doi:10.1002/cncr.27632 · Cited by 110
“of target lesions at baseline, mm 85 (15-382) 108 (11-466) 80 (11-359)”
BackgroundInfluentialSelf-citationPeeters, M., Strickland, A. H., Lichinitser, M., Suresh, A. V. S., Manikhas, G., Shapiro, J., Rogowski, W., Huang, X., Wu, B., Warner, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.594 · Cited by 79
“…recurrent ovarian cancer indicated a dose-response relationship (Karlan et al, 2012), and an exposure-response analysis of the results suggested that greater improvements in PFS might be achieved in that setting by administering trebananib at concentrations greater than 10 mg kg 1 (Lu et al, 2011).”
ResultEatock, M. M., Tebbutt, N. C., Bampton, C. L., Strickland, A. H., Valladares-Ayerbes, M., Swieboda-Sadlej, A., Van Cutsem, E., Nanayakkara, N., Sun, Y.-N., Zhong, Z. D., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds502 · Cited by 64
Self-citationReardon, D. A., Lassman, A. B., Schiff, D., Yunus, S. A., Gerstner, E. R., Cloughesy, T. F., Lee, E. Q., Gaffey, S. C., Barrs, J., Bruno, J., et al. (2018) · Cancer · doi:10.1002/cncr.31172 · Cited by 50
Metadata
- Authors
- Lu, J.-F., Rasmussen, E., Karlan, B. Y., Vergote, I. B., Navale, L., Kuchimanchi, M., Melara, R., Stepan, D. E., Weinreich, D. M., & Sun, Y.-N.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2012-01-01
- Volume
- 69
- Issue
- 5
- Pages
- 1135-1144
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2028656738
- Cited by
- 36
- References
- 1
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. https://app.cochat.ai/papers/10.1007/s00280-011-1787-5
- The paper
- Lu, J.-F., Rasmussen, E., Karlan, B. Y., Vergote, I. B., Navale, L., Kuchimanchi, M., Melara, R., Stepan, D. E., Weinreich, D. M., & Sun, Y.-N. (2012). Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-011-1787-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.